← Leaderboards
Joseph Arboleda-Velasquez
Schepens Eye Research Institute
$8,724,164
Attributed
$13,059,349
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,059,349 · 8
By mechanism
RM1$3,821,618 · 1
RF1$3,574,879 · 1
UF1$2,204,584 · 1
U01$1,529,075 · 1
UH3$739,170 · 1
R00$735,550 · 1
Top collaborators
- Diego Sepulveda-Falla2 shared
- David Fernando Aguillon1 shared
- Yakeel T. Quiroz1 shared
Most similar at Schepens Eye Research Institute
Same institution · by research overlap
- Diego Sepulveda-Falla$1,787,440
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelNotch ProteinSignal TransductionBlood VesselsPublishingMicrovascular DysfunctionMolecularReceptorLinkBrainMutationPathologyBaseNotch3 GeneTissuesAffectRetinaAutopsyCellsHuman TissueCerebrumCell SurvivalLeadDementia
Grant awards (16)
Humanization of a Notch 3 Agonist Antibody for Pre-Clinical Development of a CADASIL Treatment$730,826
U01 · FY2025 · NS · contact PI
Humanization of a Notch 3 Agonist Antibody for Pre-Clinical Development of a CADASIL Treatment$798,249
U01 · FY2024 · NS · contact PI
Resilience to Cognitive Decline and Resistance to Alzheimer's Disease and Related Neurodegenerative Diseases in Individuals from Colombia with Autosomal Dominant Dementias$3,821,618
RM1 · FY2023 · NS
Humanization of a Notch 3 agonist antibody for pre-clinical development of a CADASIL treatment$2,204,584
UF1 · FY2021 · NS · contact PI
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice$245,572
UH3 · FY2020 · NS · contact PI
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice$245,673
UH3 · FY2019 · NS · contact PI
Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASIL$49,896
RF1 · FY2019 · NS · contact PI
Charting vascular contributions to white matter disease in familial Alzheimer's disease and CADASIL$3,524,983
RF1 · FY2018 · NS · contact PI
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice$247,925
UH3 · FY2018 · NS · contact PI
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice$138,926
UH2 · FY2017 · NS · contact PI
Notch and TGF-beta in the Control of Retinal Vascular Integrity$246,279
R00 · FY2016 · EY · contact PI
Exploring the Role of Aging in Cerebral Ischemic Small Vessel Disease Using Notch3 Mutant Mice$138,205
UH2 · FY2016 · NS · contact PI
Notch and TGF-beta in the Control of Retinal Vascular Integrity$240,322
R00 · FY2015 · EY · contact PI
Notch and TGF-beta in the Control of Retinal Vascular Integrity$248,949
R00 · FY2014 · EY · contact PI
Notch and TGF-beta in the Control of Retinal Vascular Integrity$87,380
K99 · FY2013 · EY · contact PI
Notch and TGF-beta in the Control of Retinal Vascular Integrity$89,962
K99 · FY2012 · EY · contact PI